Nicox Past Earnings Performance
Past criteria checks 0/6
Nicox has been growing earnings at an average annual rate of 52.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 36.8% per year.
Key information
52.5%
Earnings growth rate
59.4%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -36.8% |
| Return on equity | -51.1% |
| Net Margin | -501.7% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nicox makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 5 | -23 | 5 | 0 |
| 31 Mar 23 | 4 | -26 | 6 | 0 |
| 31 Dec 22 | 3 | -28 | 7 | 0 |
| 30 Sep 22 | 5 | -38 | 7 | 0 |
| 30 Jun 22 | 7 | -49 | 7 | 0 |
| 31 Mar 22 | 7 | -46 | 7 | 0 |
| 31 Dec 21 | 7 | -44 | 7 | 0 |
| 30 Sep 21 | 10 | -29 | 7 | 0 |
| 30 Jun 21 | 12 | -15 | 6 | 0 |
| 31 Mar 21 | 12 | -17 | 7 | 0 |
| 31 Dec 20 | 13 | -18 | 7 | 0 |
| 30 Sep 20 | 8 | -25 | 7 | 0 |
| 30 Jun 20 | 4 | -33 | 7 | 0 |
| 31 Mar 20 | 5 | -26 | 8 | 0 |
| 31 Dec 19 | 7 | -19 | 8 | 0 |
| 30 Sep 19 | 8 | -15 | 8 | 0 |
| 30 Jun 19 | 9 | -11 | 9 | 0 |
| 31 Mar 19 | 7 | -15 | 9 | 0 |
| 31 Dec 18 | 4 | -18 | 10 | 0 |
| 30 Jun 18 | 3 | -4 | 9 | 0 |
| 31 Mar 18 | 2 | -6 | 9 | 0 |
| 31 Dec 17 | 2 | -8 | 10 | 0 |
| 30 Jun 17 | 0 | -6 | 9 | -7 |
| 31 Mar 17 | 0 | -6 | 9 | -3 |
| 31 Dec 16 | 0 | -7 | 9 | 0 |
| 30 Sep 16 | 0 | -15 | 9 | 5 |
| 30 Jun 16 | 0 | -22 | 9 | 10 |
| 31 Mar 16 | 0 | -21 | 10 | 8 |
| 31 Dec 15 | 0 | -20 | 11 | 6 |
| 30 Jun 15 | 4 | -21 | 20 | 5 |
| 31 Mar 15 | 5 | -22 | 22 | 5 |
| 31 Dec 14 | 6 | -22 | 24 | 4 |
| 30 Jun 14 | 2 | -13 | 14 | 3 |
| 31 Mar 14 | 1 | -13 | 13 | 4 |
| 31 Dec 13 | 0 | -11 | 11 | 4 |
Quality Earnings: NXOA is currently unprofitable.
Growing Profit Margin: NXOA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NXOA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NXOA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXOA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: NXOA has a negative Return on Equity (-51.14%), as it is currently unprofitable.